Status:
UNKNOWN
Resuscitation With Albumin 5% in Dengue Haemorrhagic Fever
Lead Sponsor:
Indonesia University
Conditions:
Dengue Hemorrhagic
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
Endothelial cell had important role in plasma leakage process. Plasma leakage occurs due to increased vascular permeability caused by disruption of endothelial glycocalyx showed by increased syndecan-...
Detailed Description
This study is an open label randomized control trial with concealment procedure which is to compare the effect of albumin 5% and ringer lactate towards plasma leakage incidence in adult DHF patient. T...
Eligibility Criteria
Inclusion
- Patients aged ≥ 18 and ≤ 60 years
- Patients with a history of fever ≤ 3 days, with NS1 positive, and diagnosed with DHF which marked by plasma leakage in microvascular that characterized by lactate levels ≥ 2.5 mmol / L and increased haematocrit ≥ 10% but ≤15 % of initial haematocrit. And may or not be accompanied by the presence of pleural effusion or ascites in abdominal ultrasound.
- Patients are hospitalized at RSUD Tangerang Selatan, RS Hermina Ciputat, RSUD Cengkareng,RSUD Taman Sari, RSUD Kembangan, and RS Royal Taruma from January 2018 to February 2019.
Exclusion
- Patients who are pregnant and confirmed by tests β HCG, or in menstruation cycle.
- Patients with comorbid diseases such as metabolic syndrome, liver cirrhosis, sepsis, renal disorders, hematological disorders, immunocompromised, and malnutrition.
- Refuse to participate in the study.
Key Trial Info
Start Date :
October 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2019
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT04076254
Start Date
October 1 2016
End Date
September 1 2019
Last Update
September 3 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RSAB Harapan Kita
Jakarta, Indonesia, 11420